Evidence map›Paper›PMID 24466023›Full record

ArticlePloS one2014

Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro.

Verena Rombach-Riegraf, Anette C Karle, Babette Wolf, Laetitia Sordé, Stephan Koepke, Sascha Gottlieb, Jennifer Krieg, Marie-Claude Djidja, Aida Baban, Sebastian Spindeldreher and 2 more

Erratum issuedAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 79 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

12 authors.

Verena Rombach-RiegrafNovartis Pharma AG, Technical R&D, Biologics Process R&D, Late Phase Analytical & Pharmaceutical Development, Werk Klybeck, Basel, Switzerland.
Anette C KarleNovartis Pharma AG, Integrated Biologics Profiling Unit, Immunogenicity Risk Assessment, Werk Klybeck, Basel, Switzerland.
Babette WolfNovartis Pharma AG, Pre-clinical Safety, Biologics Safety and Disposition, Experimental Pathology, Immunosafety, Werk Klybeck, Basel, Switzerland.
Laetitia SordéNovartis Pharma AG, Integrated Biologics Profiling Unit, Immunogenicity Risk Assessment, Werk Klybeck, Basel, Switzerland.
Stephan KoepkeNovartis Pharma AG, Integrated Biologics Profiling Unit, Immunogenicity Risk Assessment, Werk Klybeck, Basel, Switzerland.
Sascha GottliebNovartis Pharma AG, Integrated Biologics Profiling Unit, Immunogenicity Risk Assessment, Werk Klybeck, Basel, Switzerland.
Jennifer KriegNovartis Pharma AG, Pre-clinical Safety, Biologics Safety and Disposition, Experimental Pathology, Immunosafety, Werk Klybeck, Basel, Switzerland.
Marie-Claude DjidjaNovartis Pharma AG, Technical R&D, Biologics Process R&D, Late Phase Analytical & Pharmaceutical Development, Werk Klybeck, Basel, Switzerland.
Aida BabanNovartis Pharma AG, Pre-clinical Safety Biologics Safety and Disposition, Bioanalytics, Werk Klybeck, Basel, Switzerland.
Sebastian SpindeldreherNovartis Pharma AG, Pre-clinical Safety Biologics Safety and Disposition, Bioanalytics, Werk Klybeck, Basel, Switzerland.
Atanas V KoulovNovartis Pharma AG, Technical R&D, Biologics Process R&D, Late Phase Analytical & Pharmaceutical Development, Werk Klybeck, Basel, Switzerland.
Andrea KiesslingNovartis Pharma AG, Pre-clinical Safety, Biologics Safety and Disposition, Experimental Pathology, Immunosafety, Werk Klybeck, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Subvisible proteinaceous particles which are present in all therapeutic protein formulations are in the focus of intense discussions between health authorities, academics and biopharmaceutical companies in the context of concerns that such particles could promote unwanted immunogenicity via anti-drug antibody formation. In order to provide further understanding of the subject, this study closely examines the specific biological effects proteinaceous particles may exert on dendritic cells (DCs) as the most efficient antigen-presenting cell population crucial for the initiation of the adaptive immune response. Two different model IgG antibodies were subjected to three different types of exaggerated physical stress to generate subvisible particles in far greater concentrations than the ones typical for the currently marketed biotherapeutical antibodies. The aggregated samples were used in in vitro biological assays in order to interrogate the early DC-driven events that initiate CD4 T-cell dependent humoral adaptive immune responses--peptide presentation capacity and co-stimulatory activity of DCs. Most importantly, antigen presentation was addressed with a unique approach called MHC-associated Peptide Proteomics (MAPPs), which allows for identifying the sequences of HLA-DR associated peptides directly from human dendritic cells. The experiments demonstrated that highly aggregated solutions of two model mAbs generated under controlled conditions can induce activation of human monocyte-derived DCs as indicated by upregulation of typical maturation markers including co-stimulatory molecules necessary for CD4 T-cell activation. Additional data suggest that highly aggregated proteins could induce in vitro T-cell responses. Intriguingly, strong aggregation-mediated changes in the pattern and quantity of antigen-derived HLA-DR associated peptides presented on DCs were observed, indicating a change in protein processing and presentation. Increasing the amounts of subvisible proteinaceous particles correlated very well with the pronounced increase in the peptide number and clusters presented in the context of class II HLA-DR molecules, suggesting a major involvement of a mass-action mechanism of altering the presentation.

Indexed as

Antibodies, MonoclonalAntigen PresentationAntigen-Presenting CellsCD4-Positive T-LymphocytesDendritic CellsHLA-DR AntigensHumansRecombinant ProteinsAntibodies, MonoclonalHLA-DR AntigensRecombinant Proteins

Identifiers

PMID24466023
PMCPMC3897673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.